Previous close | 6.70 |
Open | 6.35 |
Bid | 5.50 |
Ask | 8.10 |
Strike | 5.00 |
Expiry date | 2024-01-19 |
Day's range | 6.35 - 6.35 |
Contract range | N/A |
Volume | |
Open interest | 69 |
We can readily understand why investors are attracted to unprofitable companies. For example, although...
The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.
Novavax stands out with its more traditional, protein-based COVID-19 vaccine; MannKind is making a name for itself with inhaled therapies for diabetics and patients with lung disorders; and Anavex has a promising Alzheimer's therapy.